financingEvonetix extends Series B financing to US$54mBritish Evonetix Ltd has added US$$24m to its existing US$30m Series B financing round. The new financing was led by existing investor Foresite Capital. more ➔
financingGermany’s Curevac offers common sharesmRNA vaccine pioneer CureVac N.V. has announced that it will sell US$200m of its common shares in an underwritten public offering. more ➔
partnershipsChong Kun Dang Pharm licences Synaffix ADC platformSouth Korean Chong Kun Dang Pharm has licenced access to Amsterdam-based Synaffix BV’s propietary ADC platform. more ➔
Clinical trialsNew EU stakeholder platform to speed up clinical trialsA new platform is set to facilitate the exchange of information on the optimisation of the electronic reporting system CTIS. more ➔
Novel Food Ultra-processed foods increase risk for cancerBritish researchers have linked higher consumption of ultra-processed foods to an increased risk of developing and dying from cancer. more ➔
partnershipLonza collaborates with Asher Biotherapeutics IncAsher Biotherapeutics Inc has expanded its manufacturing agreement with Lonza to include the manufacturing of AB248. more ➔
partnershipEvotec and Janssen team up in immunoncologyEvotec SE and Janssen Biotech Inc have agreed to co-develop targeted immuno-oncological therapies. more ➔
pixabay.com/SD-PicturesClimate changeEvidence of deliberate climate damageA new study adds weight to ongoing legal and political investigations against ExxonMobil for deliberate climate malfeasance. more ➔
financingRewind Therapeutics extends Series A financingWith Sunstone Life Siences A/S as a new investor, Belgian remyelination specialist Rewind Therapeutics has increased its 2018 Series A funding. more ➔
infectionNew polymer can stop biofilm formation British researchers have created a new polymer material that may help to prevent urinary tract infections caused by catheters more ➔
pixabay.com/SD-Pictures
